Info on biomarkersThe ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.
Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in
blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures.
Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.
NEUROLOGY ASSAYS Available for Scientific Research
Alpha-Synuclein Aβ40 Aβ42 BDNF GFAP MMP-9 Neuro 4-Plex B Neurology 2-Plex A (Tau, Aβ42) Neurology 3-Plex A (Tau, Aβ42, Aβ40) Neurology 4-Plex A (NF-light®, Tau, GFAP*, UCHL-1*) NF-light® NF-light® Advantage Kit (SR-X) NSE P-Tau 181 P-Tau 231 pNF-Heavy Tau Tau (mouse) TDP-43 UCH-L1